Scientists investigate drug resistance in lung cancer treatment

NCT ID NCT07199959

Recruiting now Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This observational study aims to understand how ROS1-positive non-small cell lung cancer develops resistance to the drug entrectinib. Researchers will analyze blood and tissue samples from 38 patients who have already taken entrectinib as part of their regular care. By looking at genetic changes, they hope to identify the mechanisms behind acquired resistance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Entrectinib
What this could lead to: If successful, this could help doctors understand why some lung cancers stop responding to entrectinib, potentially leading to better treatment strategies.
What could go wrong: This is a small, observational study that only looks back at past data. It won't test new treatments, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER ROS1 FUSION POSITIVE

Contacts and locations

Locations

Fudan university shanghai cancer center
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.